| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
84,190,000 |
| Market
Cap: |
10.84(B) |
| Last
Volume: |
427,350 |
Avg
Vol: |
426,157 |
| 52
Week Range: |
$67.31 - $157.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 16.7 |
| Insider 3/6 Months : 17.3 |
|
| Guru Rank Number : 983 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
75,225 |
143,757 |
247,027 |
| Total Buy Value |
$0 |
$5,942,300 |
$13,295,068 |
$24,257,422 |
| Total People Bought |
0 |
2 |
3 |
3 |
| Total Buy Transactions |
0 |
2 |
5 |
7 |
| Total Shares Sold |
24,096 |
24,096 |
39,096 |
39,954 |
| Total Sell Value |
$2,990,141 |
$2,990,141 |
$4,590,941 |
$4,685,252 |
| Total People Sold |
6 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
6 |
7 |
8 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rodino-Klapac Louise |
Head of R&D, CSO |
• – – |
2023-03-06 |
4 |
D |
$157.21 |
$178,276 |
D/D |
(1,134) |
66,582 |
|
- |
|
| Barry Richard |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,523 |
2,929,842 |
|
- |
|
| Behrens M Kathleen |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,523 |
159,993 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,523 |
20,994 |
|
- |
|
| Nicaise Claude |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,523 |
16,328 |
|
- |
|
| Boor Kathryn Jean |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,523 |
6,431 |
|
- |
|
| Mayo Stephen |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,523 |
7,910 |
|
- |
|
| Brown Ryan Edward |
SVP, General Counsel |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
28,820 |
|
- |
|
| Brown Ryan Edward |
SVP, General Counsel |
• – – |
2023-03-06 |
4 |
D |
$157.21 |
$208,303 |
D/D |
(1,325) |
24,320 |
|
- |
|
| Estepan Ian Michael |
Chief Financial Officer |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
35,423 |
|
- |
|
| Estepan Ian Michael |
Chief Financial Officer |
• – – |
2023-03-06 |
4 |
D |
$157.21 |
$215,378 |
D/D |
(1,370) |
30,923 |
|
- |
|
| Arif Bilal |
Chief Tech Ops Officer |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
26,988 |
|
- |
|
| Arif Bilal |
Chief Tech Ops Officer |
• – – |
2023-03-06 |
4 |
D |
$157.21 |
$53,451 |
D/D |
(340) |
22,488 |
|
- |
|
| Chambers Michael Andrew |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,523 |
6,431 |
|
- |
|
| Estepan Ian Michael |
Chief Financial Officer |
• – – |
2023-03-01 |
4 |
D |
$147.57 |
$55,781 |
D/D |
(378) |
32,293 |
|
- |
|
| Brown Ryan Edward |
SVP, General Counsel |
• – – |
2023-03-01 |
4 |
D |
$147.57 |
$28,924 |
D/D |
(196) |
25,645 |
|
- |
|
| Rodino-Klapac Louise |
Head of R&D, CSO |
• – – |
2023-03-01 |
4 |
D |
$147.57 |
$77,032 |
D/D |
(522) |
67,716 |
|
- |
|
| Arif Bilal |
Chief Tech Ops Officer |
• – – |
2023-03-01 |
4 |
D |
$147.57 |
$37,188 |
D/D |
(252) |
22,828 |
|
- |
|
| Arif Bilal |
Chief Tech Ops OfficerOfficer |
• – – |
2022-12-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,917 |
|
-4% |
|
| Behrens M Kathleen |
Director |
– • – |
2022-12-19 |
4 |
OE |
$34.92 |
$698,400 |
D/D |
20,000 |
158,470 |
|
- |
|
| Mayo Stephen |
Director |
– • – |
2022-11-17 |
4 |
S |
$109.92 |
$94,311 |
D/D |
(858) |
6,387 |
|
-25% |
|
| Rodino-Klapac Louise |
Head of R&D, CSO |
• – – |
2022-11-17 |
4 |
D |
$108.52 |
$456,978 |
D/D |
(4,211) |
67,998 |
|
- |
|
| Chambers Michael Andrew |
Director |
– • – |
2022-09-14 |
4 |
B |
$103.87 |
$5,963,124 |
D/D |
57,100 |
108,178 |
2.39 |
16% |
|
| Chambers Michael Andrew |
Director |
– • – |
2022-08-19 |
4 |
B |
$108.20 |
$4,999,230 |
D/D |
46,170 |
51,078 |
2.39 |
20% |
|
| Chambers Michael Andrew |
Director |
– • – |
2022-06-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
75,194 |
|
54% |
|
360 Records found
|
|
Page 3 of 15 |
|
|
1.38 (1.08%) 
